Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8793256rdf:typepubmed:Citationlld:pubmed
pubmed-article:8793256lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:8793256lifeskim:mentionsumls-concept:C0003241lld:lifeskim
pubmed-article:8793256lifeskim:mentionsumls-concept:C1522577lld:lifeskim
pubmed-article:8793256lifeskim:mentionsumls-concept:C1420282lld:lifeskim
pubmed-article:8793256pubmed:issue3lld:pubmed
pubmed-article:8793256pubmed:dateCreated1996-11-27lld:pubmed
pubmed-article:8793256pubmed:abstractTextWe performed a longitudinal follow-up study of clinical findings in 151 patients with high-titer antibodies against U1 ribonucleoprotein (U1RNP) as measured by haemagglutination. Formal connective tissue disease (CTD) diagnoses were assigned and diagnostic transitions analysed. One-hundred eighteen females and 33 males entered the study; the mean duration of follow-up was 7.1 years. Mean age at entry was 34.7 years; 73% of the patients had early disease (duration < 2 years). Fifty-six patients (37%) presented with a definite diagnosis, most often mixed connective tissue disease (MCTD, n = 40), followed by systemic lupus erythematosus (SLE, n = 11) and systemic sclerosis (SSc, n = 5). Of 84 patients (56%) presenting with nonspecific symptoms of possible, "undifferentiated" CTD, 58 developed MCTD, 4 SSc and 2 SLE. By the end of the follow-up period. 127 patients had developed a well-defined CTD; final diagnoses were: MCTD (n = 97), SLE (n = 18), SSc (n = 12). We conclude that CTD in the context of high-titer anti-U1RNP antibodies may be transitive and sequential in nature, although the diagnostic criteria for MCTD previously proposed by our group seem to delimit a clinically stable condition in most patients in this subgroup.lld:pubmed
pubmed-article:8793256pubmed:languageenglld:pubmed
pubmed-article:8793256pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8793256pubmed:citationSubsetIMlld:pubmed
pubmed-article:8793256pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8793256pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8793256pubmed:statusMEDLINElld:pubmed
pubmed-article:8793256pubmed:monthMaylld:pubmed
pubmed-article:8793256pubmed:issn0770-3198lld:pubmed
pubmed-article:8793256pubmed:authorpubmed-author:HalbergPPlld:pubmed
pubmed-article:8793256pubmed:authorpubmed-author:UllmanSSlld:pubmed
pubmed-article:8793256pubmed:authorpubmed-author:WiigEElld:pubmed
pubmed-article:8793256pubmed:authorpubmed-author:Høier-MadsenM...lld:pubmed
pubmed-article:8793256pubmed:authorpubmed-author:KriegbaumN...lld:pubmed
pubmed-article:8793256pubmed:authorpubmed-author:FrandsenP BPBlld:pubmed
pubmed-article:8793256pubmed:issnTypePrintlld:pubmed
pubmed-article:8793256pubmed:volume15lld:pubmed
pubmed-article:8793256pubmed:ownerNLMlld:pubmed
pubmed-article:8793256pubmed:authorsCompleteYlld:pubmed
pubmed-article:8793256pubmed:pagination254-60lld:pubmed
pubmed-article:8793256pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:8793256pubmed:meshHeadingpubmed-meshheading:8793256-...lld:pubmed
pubmed-article:8793256pubmed:meshHeadingpubmed-meshheading:8793256-...lld:pubmed
pubmed-article:8793256pubmed:meshHeadingpubmed-meshheading:8793256-...lld:pubmed
pubmed-article:8793256pubmed:meshHeadingpubmed-meshheading:8793256-...lld:pubmed
pubmed-article:8793256pubmed:meshHeadingpubmed-meshheading:8793256-...lld:pubmed
pubmed-article:8793256pubmed:meshHeadingpubmed-meshheading:8793256-...lld:pubmed
pubmed-article:8793256pubmed:meshHeadingpubmed-meshheading:8793256-...lld:pubmed
pubmed-article:8793256pubmed:meshHeadingpubmed-meshheading:8793256-...lld:pubmed
pubmed-article:8793256pubmed:meshHeadingpubmed-meshheading:8793256-...lld:pubmed
pubmed-article:8793256pubmed:meshHeadingpubmed-meshheading:8793256-...lld:pubmed
pubmed-article:8793256pubmed:meshHeadingpubmed-meshheading:8793256-...lld:pubmed
pubmed-article:8793256pubmed:meshHeadingpubmed-meshheading:8793256-...lld:pubmed
pubmed-article:8793256pubmed:meshHeadingpubmed-meshheading:8793256-...lld:pubmed
pubmed-article:8793256pubmed:meshHeadingpubmed-meshheading:8793256-...lld:pubmed
pubmed-article:8793256pubmed:meshHeadingpubmed-meshheading:8793256-...lld:pubmed
pubmed-article:8793256pubmed:meshHeadingpubmed-meshheading:8793256-...lld:pubmed
pubmed-article:8793256pubmed:year1996lld:pubmed
pubmed-article:8793256pubmed:articleTitleFollow-up of 151 patients with high-titer U1RNP antibodies.lld:pubmed
pubmed-article:8793256pubmed:affiliationDepartment of Nephrology, Hvidovre University Hospital, Denmark.lld:pubmed
pubmed-article:8793256pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8793256lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8793256lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8793256lld:pubmed